What data sources does EL7.AI use?

EL7.AI uses official data from the Federal Reserve (FOMC), European Central Bank, CFTC (COT reports), BLS, FRED, FMP for prices, and 15+ news sources.

What is the DLS system?

Dictionary-based Linguistic Scoring — a proprietary tone analysis system using a dictionary of 800+ categorized phrases. Reproducible and verifiable results, unlike random AI analysis.

How is EL7.AI different from Bloomberg?

Bloomberg takes years to master and costs $25,000/year. EL7.AI offers the same institutional data with built-in AI analysis at $500/year, with full Arabic support.

What markets are covered?

Stocks from 7 exchanges (NYSE, NASDAQ, LSE, TSE, HKSE, Euronext, XETRA, Tadawul), 28 forex pairs, 300+ cryptocurrencies, 50+ indices, and 40+ commodities.

Is EL7.AI available in Arabic?

Yes! EL7.AI is an Arabic-first platform — everything is available in Arabic with full RTL support: interface, analysis, news, and reports.

How much does EL7.AI cost?

Founding member pricing starts at $500/year (Batch 1). The price is locked forever at this level. Regular pricing will be $1,000/year after official launch.

Is there a refund policy?

Yes — full refund within 7 days of purchase. If you're not satisfied, contact us for a complete refund.

Bank of Japan and Bank of England with DLS, advanced crypto module, enhanced trading signals, and mobile app. All future features are included in your subscription.

Hims & Hers Announces $1.2 Billion Global Expansion via Eucalyptus Acquisition

Hims & Hers Health (HIMS) has announced a significant $1.2 billion international expansion through the acquisition of Eucalyptus. The strategic move is designed to scale the company’s personalized wellness platform and establish a robust international presence. By acquiring Eucalyptus, Hims & Hers aims to diversify its revenue streams and mitigate risks associated with its GLP-1 weight-loss drug segment. Market analysts view this acquisition as a proactive step to address investor concerns regarding the long-term sustainability of its current business model. The expansion allows the company to leverage its health-tech expertise across new geographical markets. This $1.2 billion investment underscores the firm's commitment to becoming a dominant global player in the personalized healthcare sector.

Hims & Hers Announces $1.2 Billion Global Expansion via Eucalyptus Acquisition

Instruments